Elite Trades From Anywhere

$100 Off Your First Year

00
Days
00
Hours
00
Mins
00
Sec
Claim Now
Index
RUT
Market Cap
1.56B
Enterprise Value
1.82B
Income
-104.56M
Sales
204.73M
Book/sh
1.43
Cash/sh
0.64
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
435
IPO
Nov 20, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
7.62
P/B
4.21
P/C
9.40
P/FCF
-
EV/EBITDA
107.17
EV/Sales
8.90
Quick Ratio
4.96
Current Ratio
5.91
Debt/Eq
1.28
LT Debt/Eq
1.25
Option/Short
Yes / Yes
EPS (ttm)
-0.72
EPS next Y
-0.09
EPS next Q
-0.04
EPS this Y
60.65%
EPS next Y
18.67%
EPS next 5Y
43.44%
EPS past 3/5Y
- -
Sales past 3/5Y
-40.53% -8.15%
EPS Y/Y TTM
37.09%
Sales Y/Y TTM
-15.35%
EPS Q/Q
87.79%
Sales Q/Q
40.53%
Insider Own
27.96%
Insider Trans
-0.07%
Inst Own
72.95%
Inst Trans
-2.11%
ROA
-12.50%
ROE
-40.83%
ROIC
-21.92%
Gross Margin
28.41%
Oper. Margin
-20.29%
Profit Margin
-51.07%
SMA20
10.47%
SMA50
28.53%
SMA200
64.84%
Trades
Shs Outstand
147.50M
Shs Float
106.26M
52W High
6.55 -7.79%
52W Low
1.99 203.52%
Volatility
6.28% 5.68%
ATR (14)
0.31
RSI (14)
70.21
Beta
0.64
Rel Volume
0.63
Avg Volume
2.74M
Volume
1,720,726
Perf Week
-1.31%
Perf Month
25.05%
Perf Quarter
110.45%
Perf Half Y
84.71%
Perf YTD
85.85%
Perf Year
127.92%
Perf 3Y
-51.41%
Perf 5Y
-84.62%
Perf 10Y
-
Prev Close
6.15
Price
6.04
Change
-1.79%
Date Action Analyst Rating Change Price Target Change
Feb-26-25Downgrade Robert W. Baird Outperform → Neutral $9 → $3
Dec-19-24Initiated Guggenheim Neutral
Dec-05-24Downgrade Goldman Neutral → Sell $4.25
Nov-14-24Initiated Wolfe Research Peer Perform
Nov-08-24Downgrade William Blair Outperform → Mkt Perform
Aug-28-24Initiated Wells Fargo Overweight $10
Aug-13-24Downgrade Morgan Stanley Overweight → Equal-Weight $11 → $10
Apr-10-24Initiated Craig Hallum Buy $15
Dec-12-23Upgrade BofA Securities Neutral → Buy $10 → $8
Aug-08-23Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jun-16-26 08:30AM
Jun-03-26 08:30AM
May-18-26 04:00PM
May-08-26 08:30AM
May-07-26 04:01PM
04:05PM Loading…
Apr-20-26 04:05PM
Feb-26-26 08:30AM
02:11AM
Feb-25-26 07:25PM
04:01PM
Feb-09-26 05:05PM
Nov-10-25 08:00AM
Nov-07-25 12:12AM
Nov-06-25 06:15PM
04:01PM
09:05AM Loading…
Nov-04-25 09:05AM
Oct-22-25 04:01PM
Aug-12-25 03:07AM
Aug-11-25 07:00PM
04:05PM
Jul-28-25 05:08PM
Jun-25-25 04:01PM
Jun-09-25 08:30AM
Jun-03-25 10:00AM
May-21-25 04:22PM
04:05PM
May-20-25 08:00AM
May-14-25 04:00PM
May-13-25 09:30AM
03:11AM
05:20PM Loading…
May-12-25 05:20PM
04:06PM
May-08-25 05:10PM
May-07-25 07:10PM
May-05-25 05:47AM
May-01-25 05:20PM
07:30AM
Apr-24-25 12:27PM
Apr-22-25 05:45AM
Apr-16-25 06:10PM
Apr-15-25 09:35AM
Apr-14-25 01:13PM
Apr-11-25 01:31PM
Apr-10-25 11:34AM
04:37AM
Apr-04-25 02:34PM
Apr-03-25 06:21PM
Apr-01-25 01:23PM
Mar-26-25 11:10AM
Mar-25-25 12:49PM
Mar-24-25 02:33PM
Mar-22-25 10:30AM
Mar-21-25 08:00PM
01:43PM
Mar-20-25 09:00PM
Mar-18-25 04:05PM
05:45AM
Mar-17-25 02:22AM
Mar-16-25 09:32AM
Mar-08-25 10:15AM
Feb-28-25 09:31AM
Feb-27-25 06:37PM
Feb-25-25 06:00AM
Feb-24-25 08:00AM
Feb-04-25 04:01PM
Feb-03-25 06:00AM
Jan-28-25 04:01PM
Jan-20-25 11:02PM
Jan-08-25 04:10PM
Dec-20-24 07:15AM
Dec-05-24 04:05PM
Nov-12-24 08:05AM
Nov-09-24 06:51AM
Nov-08-24 02:20PM
03:15AM
02:34AM
Nov-07-24 04:01PM
04:01PM
Oct-15-24 04:05PM
Oct-09-24 08:03AM
Sep-24-24 08:12AM
Aug-28-24 07:49AM
Aug-12-24 08:05AM
Aug-08-24 12:45AM
Aug-07-24 04:05PM
Jul-29-24 04:05PM
Jul-10-24 08:00AM
Jul-02-24 04:00PM
Jun-20-24 09:15AM
Jun-17-24 09:54AM
Jun-12-24 02:38AM
May-17-24 11:52AM
May-13-24 08:00AM
May-09-24 04:18PM
04:05PM
10:53AM
10:11AM
04:02AM
03:15AM
May-08-24 08:57PM
Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm's brands include TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. It operates through the TriLink and Cygnus segments. The TriLink segment manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Cygnus segment sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. It also operates through the following geographical segments: North America, Asia Pacific, Europe, the Middle East, and Africa, and Latin and Central America. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
Chairman of the BoardMr. Robert Andrew Eckert M.B.A.
CEO & DirectorMr. Bernd Brust
EVP & Chief Financial OfficerMr. Rajesh J. Asorpota
Executive VPMr. Kurt A. Oreshack J.D.
Executive VP & GM of Cygnus TechnologiesMs. Christine Dolan
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORESHACK KURTGeneral CounselJun 10 '26Sale5.1025,000127,500335,767Jun 10 05:06 PM
ORESHACK KURTGeneral CounselJun 09 '26Sale5.0625,000126,500360,767Jun 10 05:06 PM
ORESHACK KURTOfficerJun 10 '26Proposed Sale5.1025,000127,500Jun 10 12:00 PM
ORESHACK KURTOfficerJun 09 '26Proposed Sale5.0625,000126,500Jun 09 10:31 AM
PRAHALAD MURALIFormer DirectorDec 23 '25Proposed Sale3.333,95113,138Dec 23 03:00 PM
Hopfield JessicaFormer DirectorDec 19 '25Proposed Sale3.4853,951187,526Dec 19 04:38 PM
LUCIER GREGORY TDirectorDec 05 '25Buy3.7051,472190,446106,595Dec 09 04:36 PM
LUCIER GREGORY TDirectorDec 08 '25Buy3.6748,528178,098155,123Dec 09 04:36 PM
Brust BerndChief Executive OfficerNov 13 '25Buy3.25216,212702,689466,771Nov 17 04:48 PM
Brust BerndChief Executive OfficerNov 11 '25Buy3.24157,201509,331157,201Nov 13 05:27 PM
Brust BerndChief Executive OfficerNov 12 '25Buy3.2193,358299,679250,559Nov 13 05:27 PM